1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
2.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FDA IND 100712, 96-MH-01, NCT00611208
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 25223, PSU25223, NCT00626626
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D1600C00001, 2008-002606-19, NCT00731263
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VGFT-ST-0708, TCD10767, NCT00794417
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-103, NCT00975767
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0051, NCI-P6720, NCT00304044
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: NCI
Protocol IDs: UMN-2005LS048, UMN-0508M72589, UMN-MT2004-24, NCT00345865
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPKC412D2201, NCT00782067
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P2 L-D AB, NCT00917826
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: SGN35-006, NCT00947856
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 64 and under
Sponsor: Other
Protocol IDs: FHCRC-2212.00, NCI-2009-01244, NCT00968630
|
|
14.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0908-04; IUCRO-0256, NCT00975975
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 09-0679-04, NCT00997386
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 0 to 26
Sponsor: Other
Protocol IDs: CHNY 525, AAAB2879, NCT01049854
|
|
17.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Under 65
Sponsor: NCI
Protocol IDs: FHCRC-1410.00, NCT00112593
|
|
18.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 2006-0764, NCT00428545
|
|
19.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 15 and over
Sponsor: NCI
Protocol IDs: MDA-MDACC-2005-0910, MDACC 2005-0910, 7534, NCT00458731
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GEM301, NCT00457574
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8081001, NCT00585195
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: H-20159, KTN10010, BMP1350, NCT00586560
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-102, NCT00679133
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 265-101, NCT00697632
|
